The LancetOriginal article
[Articles] Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
Phase 3positiveralinepagPositive
AI Analysis
Summary
Phase 3 ADVANCE OUTCOMES study demonstrates ralinepag significantly reduced risk of clinical worsening in PAH patients versus placebo, supporting oral once-daily prostacyclin-pathway treatment; however, treatment discontinuations due to adverse events were more frequent with ralinepag.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Ralinepag significantly reduced risk of first clinical worsening compared with placebo, but associated with more adverse-event-related treatment discontinuations
Importance:7/10
Sentiment:
0.65
Phase 3 datapulmonary arterial hypertensionprostacyclin pathwayoral treatmentrandomized controlled trialclinical worsening
Read the original article
Published by The Lancet on July 28, 2026 10:30 PM